Laddar...
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Bispecific antibodies have moved from being an academic curiosity with therapeutic promise to reality, with two molecules being currently commercialized (Hemlibra(®) and Blincyto(®)) and many more in clinical trials. The success of bispecific antibodies is mainly due to the continuously growing numb...
Sparad:
| I publikationen: | BioDrugs |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Springer International Publishing
2018
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6182456/ https://ncbi.nlm.nih.gov/pubmed/30132211 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-018-0299-9 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|